Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

In Vitro Drug Release Testing: Overview, Development and Validation

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

Equivalence: In Vitro and In Vivo Bioequivalence

Equivalence: In Vitro and In Vivo Bioequivalence

Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...

In Vitro Drug Dissolution: Compendial Testing Models I

In Vitro Drug Dissolution: Compendial Testing Models I

Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...

Drug Product Performance: In Vitro–In Vivo Correlation

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...

Clinically Relevant Drug Product Specifications: Methods of Establishment

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Corrigendum to "Hypothesis-driven approach to developmental toxicity assessment: Using mechanistic information to inform testing" [Reprod. Toxicol. 140 (2026) 109119].

Reproductive toxicology (Elmsford, N.Y.)·2025

Same author

Hypothesis-driven approach to developmental toxicity assessment: Using mechanistic information to inform testing.

Reproductive toxicology (Elmsford, N.Y.)·2025

Same author

A highly potent, orally bioavailable pyrazole-derived cannabinoid CB2 receptor-selective full agonist for <i>in vivo</i> studies.

bioRxiv : the preprint server for biology·2024

Same author

Trust your gut: Establishing confidence in gastrointestinal models - An overview of the state of the science and contexts of use.

ALTEX·2024

Same author

Time for CHANGE: system-level interventions for bringing forward the date of effective use of NAMs in regulatory toxicology.

Archives of toxicology·2024

Same author

Recommendations on fit-for-purpose criteria to establish quality management for microphysiological systems and for monitoring their reproducibility.

Stem cell reports·2024

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Are in vitro tests suitable for regulatory use?

Thomas Hartung¹, George Daston

¹Johns Hopkins University, Bloomberg School of Public Health, Department of Environmental Health Sciences, Center for Alternatives to Animal Testing, Doerenkamp-Zbinden-Chair for Evidence-based Toxicology, Baltimore, Maryland 21205, USA. thartung@jhsph.edu

Toxicological Sciences : an Official Journal of the Society of Toxicology

|July 21, 2009

Summary

This summary is machine-generated.

In vitro tests are not useless for regulatory toxicology. This article explores the debate on their utility, presenting arguments for and against their use to find a balanced perspective.

More Related Videos

Assessing Specificity of Anticancer Drugs In Vitro

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Screening for Endocrine Activity in Water Using Commercially-available In Vitro Transactivation Bioassays

Screening for Endocrine Activity in Water Using Commercially-available In Vitro Transactivation Bioassays

Published on: December 4, 2016

Related Experiment Videos

Last Updated: Jun 21, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Assessing Specificity of Anticancer Drugs In Vitro

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Screening for Endocrine Activity in Water Using Commercially-available In Vitro Transactivation Bioassays

Screening for Endocrine Activity in Water Using Commercially-available In Vitro Transactivation Bioassays

Published on: December 4, 2016

Area of Science:

Toxicology
Regulatory Science
Scientific Modeling

Background:

The utility of in vitro tests for regulatory toxicology has been debated, particularly concerning their limitations with input data.
A 2008 SOT/EuroTox debate framed the discussion as a thesis and antithesis on the statement 'In vitro tests are useless for regulatory use.'

Purpose of the Study:

To summarize the arguments presented in the thesis and antithesis of the in vitro testing debate.
To propose a synthesis that reconciles the opposing viewpoints on the regulatory application of in vitro tests.

Main Methods:

Review and synthesis of arguments from the 2008 SOT/EuroTox debate.
Application of Hegelian dialectics (thesis, antithesis, synthesis) to the debate.

Main Results:

The debate highlighted significant challenges and limitations of in vitro tests in regulatory toxicology.
Arguments were presented both for and against the regulatory usefulness of in vitro data.

Conclusions:

A balanced perspective is needed to effectively integrate in vitro data into regulatory toxicology.
Further development and validation are crucial for enhancing the regulatory acceptance of in vitro methods.